Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed early invasive HER2-positive carcinoma of the breast with no evidence of residual, locally recurrent, or metastatic disease and defined as clinical Stage I to IIIC that is eligible for treatment with Herceptin~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Screening left ventricular ejection fraction (LVEF) greater than or equal to (≥) 55%~Exclusion Criteria:~* Previous neoadjuvant or adjuvant breast cancer treatment with an approved or investigational anti-HER2 agent~* History of other malignancy except for curatively treated carcinoma in situ of the cervix, basal cell carcinoma, or curatively treated malignancies (other than breast cancer) where the participant has been disease-free for at least 5 years~* Past history of ductal carcinoma in situ treated with any systemic therapy or with radiation therapy to the ipsilateral breast where invasive cancer subsequently developed~* Metastatic disease~* Inadequate bone marrow, hepatic, or renal function~* Serious cardiac or cardiovascular disease including uncontrolled hypertension or history of hypertensive crisis or hypertensive encephalopathy~* History of severe allergic or immunological reactions, such as difficult-to-control asthma~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: SC Herceptin by Needle/Syringe (Type: EXPERIMENTAL): Participants will receive SC Herceptin by an assisted administration using a conventional syringe and needle/vial formulation.
- Cohort B: SC Herceptin by SID (Type: EXPERIMENTAL): Participants will receive SC Herceptin with assisted and/or self-administered use of an SID. The first administration will be performed by a trained healthcare professional. If well tolerated and the participant is willing and judged competent to perform self-administration, subsequent administration of SC Herceptin may be performed by the participant.

Based on this trial design, predict the completion outcome and termination type (if applicable).